Mad Money w/ Jim Cramer Mad Money w/ Jim Cramer 1/16/25
Jan 17, 2025
Vlad Chorch, CEO of Biohaven Ltd., discusses ongoing drug innovations for neurological disorders following their migraine drug sale to Pfizer. Brian Jordan, CEO of First Horizon, shares insights on regional banking growth and the impact of recent regulatory changes. Todd McKinnon, CEO of Okta, highlights cybersecurity advancements spurred by government actions to improve defenses. They explore the interplay between investment strategies, economic trends, and industry challenges, all while engaging with listener questions for more interactive insights.
AI Snips
Chapters
Transcript
Episode notes
CEO Frustrations with Biden
- Jim Cramer recounts his conversations with CEOs in California.
- They expressed frustration with the Biden administration's approach to business, citing overregulation.
Impact of Inflation Reduction Act
- The Biden administration's Inflation Reduction Act allows Medicare to negotiate drug prices.
- This impacts pharmaceutical company profits, a concern for investors.
Inconsistent Industrial Policies
- There's perceived inconsistency in the Biden administration's approach to different industries.
- While the CHIPS Act benefited the semiconductor industry, oil companies felt ignored.